GSK reported promising results from a Phase III trial of its new RSV vaccine in older adults. The study involved more than 25,000 participants and met its primary endpoints, showing a statistically significant reduction in RSV-related lower respiratory tract disease. GSK described the vaccine as highly effective.
The results position GSK to compete in the RSV vaccine market. A potential launch is expected in late 2027.
Several analysts upgraded their outlook on GSK stock, citing the vaccine’s potential as a blockbuster. The results add to the company’s long-term growth pipeline.